Using Artificial Intelligence-based ChatBot to Improve Women's Participation to Cervical Cancer Screening Programme
Launched by INTERNATIONAL AGENCY FOR RESEARCH ON CANCER · Mar 17, 2022
Trial Information
Current as of June 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how an artificial intelligence-based chatbot can help increase the number of women participating in cervical cancer screening programs. The goal is to make it easier for women to take an HPV self-sampling test, which can help detect the presence of the virus that may lead to cervical cancer. The study will focus on women aged 30 to 65 who live in certain areas of the Occitanie region and haven't had a Pap smear (a test to check for cervical cancer) in the last four years.
To be eligible for this trial, you should be a woman within the specified age range, live in a deprived area, and not have responded to an earlier invitation for HPV testing. If you have had a Pap smear in the last three years, are pregnant beyond six months, or have already scheduled or attended a screening appointment, you won't be able to participate. If you join the study, you can expect support from the chatbot to help you through the screening process and manage any positive results from your self-sampling test. This trial aims to improve cervical cancer prevention and ensure that more women get the care they need.
Gender
FEMALE
Eligibility criteria
- Inclusion criteria: eligible women will be:
- • aged 30-65
- • did not perform a pap smear in the last 4 years
- • are living in deprived clusters in the Occitanie region.
- • did not answer to a first "invitation" letter to perform a clinician-collected HPV testing
- Exclusion criteria: ineligible women will be those:
- • outside the target age group
- • had a Pap smear in the past 3 years
- • had hysterectomy including cervix
- • are pregnant beyond 6 months
- • already scheduled a screening appointment or had just attended a HPV screening
- • had a cervical abnormality that was under exploration and/or treatment.
- • participated to the study pilot
About International Agency For Research On Cancer
The International Agency for Research on Cancer (IARC) is a specialized agency of the World Health Organization (WHO) dedicated to promoting international collaboration in cancer research. Established in 1965, IARC aims to advance the understanding of cancer etiology and prevention through high-quality research, data collection, and analysis. By coordinating scientific efforts across countries, the agency facilitates innovative studies and clinical trials that contribute to global cancer control initiatives. IARC's commitment to fostering interdisciplinary partnerships and disseminating research findings enhances its role as a pivotal institution in the fight against cancer worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Carcassone, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials